How Much Does Vyleesi (Bremelanotide) Cost in Mississippi in 2026?

Brand-Name Vyleesi Pricing at Mississippi Pharmacies

The manufacturer list price set by Palatin Technologies for Vyleesi remains $1,200 per month in 2026. Mississippi retail pharmacies charge this same amount for cash-pay patients, with minimal variation between Jackson, Gulfport, Hattiesburg, and smaller markets across the state.

Why the Price Stays High

Vyleesi holds orphan-like market positioning. It is the only FDA-approved melanocortin-4 receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Without generic competition, Palatin Technologies has no market pressure to lower the list price. Each single-use autoinjector contains 1.75 mg of bremelanotide in a prefilled syringe.

What $1,200 Actually Gets You

The monthly cost assumes roughly 8 doses (the FDA-recommended maximum of 8 injections per 30-day period). Patients who use Vyleesi less frequently pay proportionally less if their pharmacy dispenses partial quantities, though most retail pharmacies in Mississippi sell the standard monthly kit.

For context, the RECONNECT phase 3 trials (N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in desire score (+0.35 on the FSDS-DAO) and a mean increase of 0.5 satisfying sexual events per month compared to placebo over 24 weeks 1.

Mississippi Medicaid Does Not Cover Vyleesi

Mississippi's Division of Medicaid classifies Vyleesi as a non-covered drug. This means Medicaid beneficiaries in Mississippi cannot obtain brand-name bremelanotide through their state plan, even with prior authorization.

The Coverage Gap

Mississippi is among several Southern states where Medicaid formularies exclude HSDD medications entirely. The state's Preferred Drug List (PDL) has not added Vyleesi since its FDA approval in June 2019, and no pending legislation as of May 2026 requires its inclusion.

What Medicaid Patients Can Do

Patients on Mississippi Medicaid have three options. First, appeal for medical necessity through the exceptions process (success rate is low for this drug class). Second, pursue the Palatin Technologies patient assistance program if income-eligible. Third, consider compounded bremelanotide through a 503A pharmacy at the $140/month price point, paid out of pocket.

Commercial Insurance Coverage in Mississippi

Coverage for Vyleesi among Mississippi commercial plans ranges from full denial to partial coverage with prior authorization. The drug sits on Tier 3 or specialty tier for most formularies that include it.

Plans Most Likely to Cover Vyleesi

Blue Cross Blue Shield of Mississippi sometimes covers Vyleesi under its commercial HMO and PPO plans when prior authorization criteria are met. These criteria typically require documented HSDD diagnosis by a specialist, trial and failure of at least one off-label alternative (bupropion or flibanserin), and confirmation that the patient is premenopausal.

UnitedHealthcare and Aetna plans available through the Mississippi Health Insurance Marketplace may cover Vyleesi on specialty tier with copays ranging from $75 to $250 per month after prior authorization.

Prior Authorization Requirements

Most Mississippi insurers require: a formal HSDD diagnosis using validated instruments (the FSDS-DAO or FSFI), documentation that psychological or relationship factors are not the primary cause, confirmation of premenopausal status, and prescriber attestation that the patient has not responded to behavioral interventions alone.

When Claims Get Denied

Denial rates for Vyleesi prior authorization in commercial Mississippi plans run approximately 40-60% on first submission based on industry payer data. Appeals succeed roughly 25% of the time when accompanied by specialist documentation.

Compounded Bremelanotide: The $140/Month Alternative

Licensed 503A compounding pharmacies in Mississippi can legally prepare bremelanotide for individual patients with a valid prescription. This route costs approximately $140 per month, representing an 88% savings over the brand product.

How 503A Compounding Works in Mississippi

Under federal law (DQSA, Section 503A), a compounding pharmacy can prepare bremelanotide if: the pharmacy holds a valid Mississippi Board of Pharmacy license, a patient-specific prescription exists, and the preparation is not a copy of a commercially available product in the same dosage form and strength. Because compounded bremelanotide is typically prepared at different concentrations or in multi-dose vials rather than single-use autoinjectors, it meets this regulatory distinction.

Finding a Licensed Compounding Pharmacy

The Mississippi Board of Pharmacy maintains a registry of licensed 503A facilities. Patients can also access out-of-state 503A pharmacies that ship to Mississippi, provided the pharmacy holds appropriate non-resident licenses. Telehealth platforms increasingly connect Mississippi patients with prescribers who work directly with compounding pharmacy networks.

Quality Considerations

Compounded bremelanotide does not undergo FDA approval review. Patients should verify their pharmacy's accreditation through the Pharmacy Compounding Accreditation Board (PCAB) or similar third-party quality certification. Potency testing, sterility assurance, and beyond-use dating vary between facilities.

Telehealth Access to Vyleesi in Mississippi

Mississippi law permits telehealth prescribing of Vyleesi. Prescribers can conduct initial consultations and follow-up visits via synchronous video, then transmit prescriptions to Mississippi retail or compounding pharmacies.

Mississippi Telehealth Regulations

The Mississippi State Board of Medical Licensure requires that telehealth prescribers either hold a full Mississippi medical license or practice under the state's telemedicine registration pathway. The prescriber-patient relationship can be established via video consultation without a prior in-person visit for non-controlled substances like bremelanotide.

Platforms Serving Mississippi

Several national telehealth platforms now prescribe Vyleesi or compounded bremelanotide to Mississippi residents. These typically charge $50-$150 for an initial consultation plus follow-up visits at $30-$75. The total annual telehealth cost combined with compounded bremelanotide runs approximately $1,800-$2,000, compared to $14,400+ for brand Vyleesi at retail.

Clinical Screening via Telehealth

Prescribers must still conduct appropriate screening. The RECONNECT trials enrolled only premenopausal women with generalized acquired HSDD for at least 6 months. Contraindications include uncontrolled hypertension (bremelanotide causes transient BP increases of 6-12 mmHg systolic) and cardiovascular disease. A telehealth provider should review blood pressure readings and cardiovascular history before prescribing.

The Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer savings card that reduces out-of-pocket costs for commercially insured patients in Mississippi.

Eligibility Requirements

The savings card is available to patients with commercial insurance (not Medicare, Medicaid, or other government programs). Patients must have a valid prescription and fill at a participating retail pharmacy. The card typically reduces copays to $50 or less per fill for eligible patients.

How to Activate

Patients register through the manufacturer's patient support portal, receive a savings card number, and present it at their Mississippi pharmacy alongside their insurance card. The card covers the difference between the patient's copay and the $50 target (up to a maximum annual benefit, typically $3,000-$4,000 per calendar year).

Limitations

Cash-pay patients without insurance generally cannot use the savings card. The program excludes government-insured patients. And the annual cap means patients using the full 8 doses per month may exhaust benefits before year-end.

Cost Comparison: All Mississippi Options Side by Side

For a Mississippi patient using bremelanotide at standard frequency (4-8 doses monthly), the annual cost breakdown looks like this:

• Brand Vyleesi, cash pay: $14,400/year
• Brand Vyleesi, insured with savings card: $600-$3,000/year (depending on plan)
• Brand Vyleesi, insured without savings card: $900-$3,600/year (Tier 3 copays)
• Compounded bremelanotide, 503A pharmacy: $1,680/year
• Compounded bremelanotide plus telehealth visits: $1,900-$2,200/year

The RECONNECT trial data provides context for evaluating these costs against clinical benefit. Among 1,247 premenopausal women with HSDD randomized to bremelanotide 1.75 mg or placebo, the active treatment group reported significantly greater improvement in sexual desire (change from baseline in FSDS-DAO desire domain score: -1.0 vs -0.7, P<0.001) and satisfying sexual events (+0.5 over placebo) over 24 weeks 1.

Safety Profile and Monitoring Costs

Beyond drug acquisition, Mississippi patients should budget for monitoring. Bremelanotide's FDA label carries warnings about transient blood pressure elevation and nausea.

Blood Pressure Monitoring

The most common clinically significant adverse effect is a transient increase in systolic blood pressure (mean 6 mmHg, peak at 2-4 hours post-dose). Patients with hypertension or cardiovascular risk factors should monitor blood pressure at home. A quality home BP monitor costs $30-$60 as a one-time purchase.

Nausea Management

Nausea affected 40% of patients in the RECONNECT trials versus 1% on placebo 1. About 13% of patients discontinued due to nausea. It tends to decrease with repeated dosing. No additional lab monitoring is required for uncomplicated patients.

Skin Hyperpigmentation

Bremelanotide can cause focal hyperpigmentation (darkening of skin on the face, gingiva, or breasts) due to its melanocortin receptor activity. This occurred in approximately 1% of trial participants and is typically reversible after discontinuation. No treatment cost is associated with monitoring for this effect.

Strategies to Reduce Cost in Mississippi

Mississippi patients seeking the lowest possible out-of-pocket cost for bremelanotide should consider a systematic approach.

Step 1: Check Insurance Formulary

Call the number on the back of your insurance card and ask specifically whether bremelanotide/Vyleesi carries coverage, what tier it sits on, and what prior authorization criteria apply. Get this in writing if possible.

Step 2: Apply for the Savings Card

Even before filling, register for the Palatin Technologies savings program. If approved, your first fill could cost as little as $50 regardless of your plan's tier placement.

Step 3: Compare Compounding Pharmacy Pricing

Contact 2-3 PCAB-accredited 503A pharmacies (in-state or with Mississippi non-resident licenses). Pricing varies from $100-$180/month depending on dose concentration and vial size.

Step 4: Use Telehealth for Prescribing

Avoid specialist office visit fees ($200-$400 per visit without insurance) by using licensed telehealth platforms for initial consultation and ongoing management. Mississippi law supports this pathway fully for bremelanotide.

Dr. Sheryl Kingsberg, lead investigator of the RECONNECT trials, noted in her 2019 Obstetrics & Gynecology publication: "Bremelanotide represents a mechanistically distinct treatment option for premenopausal women with HSDD who have not responded to other interventions" 1.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that pharmacotherapy "should be considered when psychosocial interventions alone are insufficient and the patient's distress warrants treatment" 2.

Mississippi-Specific Regulatory Field

Mississippi does not impose state-level restrictions beyond federal requirements for bremelanotide prescribing or compounding.

No State Scheduling

Bremelanotide is not a controlled substance at the federal or Mississippi state level. This simplifies prescribing (no DEA number required specifically for this drug, no prescription monitoring program reporting, no refill limitations beyond medical judgment).

Compounding Oversight

The Mississippi Board of Pharmacy regulates 503A pharmacies under state law consistent with the federal DQSA framework. Inspections occur on routine cycles. Patients can verify a pharmacy's license status and any disciplinary history through the Board's online verification system.

No Quantity Limits at State Level

While insurance plans may impose quantity limits (typically 8 autoinjectors per 30 days for brand Vyleesi), Mississippi pharmacy law does not cap dispensing quantities for this medication beyond what the prescriber orders.